BARI, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.333
EU - Europa 4.469
AS - Asia 4.268
SA - Sud America 684
AF - Africa 167
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 8
Totale 19.964
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.157
GB - Regno Unito 1.796
SG - Singapore 1.295
CN - Cina 1.134
IT - Italia 665
HK - Hong Kong 533
BR - Brasile 509
VN - Vietnam 485
DE - Germania 427
SE - Svezia 357
FR - Francia 283
FI - Finlandia 204
RU - Federazione Russa 190
UA - Ucraina 184
TR - Turchia 165
IN - India 103
KR - Corea 100
CA - Canada 82
BD - Bangladesh 78
ID - Indonesia 75
BG - Bulgaria 72
AR - Argentina 59
MA - Marocco 56
MX - Messico 49
IQ - Iraq 43
ZA - Sudafrica 43
JP - Giappone 36
BE - Belgio 33
ES - Italia 32
PL - Polonia 32
AU - Australia 31
LT - Lituania 30
PK - Pakistan 30
IE - Irlanda 29
EC - Ecuador 28
NL - Olanda 25
PH - Filippine 25
CO - Colombia 24
AT - Austria 23
SA - Arabia Saudita 23
AE - Emirati Arabi Uniti 21
CZ - Repubblica Ceca 20
CL - Cile 19
UZ - Uzbekistan 17
IR - Iran 13
JO - Giordania 13
MY - Malesia 13
KE - Kenya 12
CH - Svizzera 11
PY - Paraguay 11
VE - Venezuela 11
EG - Egitto 10
AZ - Azerbaigian 9
BO - Bolivia 9
PT - Portogallo 9
CR - Costa Rica 7
DZ - Algeria 7
GR - Grecia 7
JM - Giamaica 7
KG - Kirghizistan 7
NO - Norvegia 7
UY - Uruguay 7
BH - Bahrain 6
DO - Repubblica Dominicana 6
EU - Europa 6
KZ - Kazakistan 6
NP - Nepal 6
PE - Perù 6
RO - Romania 6
ET - Etiopia 5
HU - Ungheria 5
IL - Israele 5
LB - Libano 5
RS - Serbia 5
TZ - Tanzania 5
AL - Albania 4
BZ - Belize 4
GH - Ghana 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
PA - Panama 4
PS - Palestinian Territory 4
TH - Thailandia 4
TN - Tunisia 4
CI - Costa d'Avorio 3
GP - Guadalupe 3
OM - Oman 3
SN - Senegal 3
SV - El Salvador 3
CY - Cipro 2
DM - Dominica 2
HN - Honduras 2
HR - Croazia 2
NI - Nicaragua 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
Totale 19.935
Salva come PNG Salva come JPEG
Città #
Southend 1.448
Fairfield 1.059
Ashburn 983
Santa Clara 900
Singapore 832
Woodbridge 702
Hong Kong 523
Houston 505
Chandler 497
Seattle 443
Wilmington 401
Cambridge 380
Ann Arbor 327
San Jose 324
Jacksonville 314
Beijing 270
Dearborn 261
Hefei 252
Nyköping 246
Chicago 199
London 192
Los Angeles 184
Modena 181
Ho Chi Minh City 153
New York 141
Helsinki 132
Council Bluffs 130
Hanoi 110
San Diego 106
Shanghai 96
Frankfurt am Main 95
Seoul 95
The Dalles 95
Salt Lake City 82
Princeton 76
Moscow 70
Sofia 70
Izmir 64
São Paulo 63
Eugene 61
Munich 60
Jakarta 55
Lauterbourg 52
Milan 49
Casablanca 42
Buffalo 39
Dallas 39
Bremen 35
Elk Grove Village 34
Columbus 33
Redwood City 33
Bologna 32
Fremont 31
Rome 31
Brussels 28
Da Nang 28
Warsaw 28
Falls Church 27
Phoenix 27
Boardman 26
Dublin 26
Tampa 26
Montreal 25
Tokyo 23
Johannesburg 22
Orem 21
Dong Ket 20
Toronto 20
Sterling 19
Turku 19
Denver 17
Nanjing 17
Norwalk 17
Rio de Janeiro 17
Chengdu 16
Des Moines 16
Dhaka 16
Lancaster 16
Baghdad 15
Guangzhou 15
Poplar 15
Brooklyn 14
Nuremberg 14
Guayaquil 13
San Giuliano Milanese 13
Stockholm 13
Tashkent 13
Buenos Aires 12
Detroit 12
Mumbai 12
Paris 12
Amman 11
Amsterdam 11
Boston 11
Chennai 11
Haiphong 11
Lahore 11
Latina 11
Nairobi 11
Ottawa 11
Totale 14.416
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 605
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 507
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 484
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 465
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 426
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 426
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 423
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 415
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 405
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 399
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 379
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 375
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 372
Activity of BKM120 and BEZ235 against lymphoma cells 364
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 359
Empathic attitudes among nursing students: a preliminary study 357
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 356
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 355
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 341
A concise review of lenalidomide therapy for follicular lymphoma 336
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 328
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 327
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 315
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 312
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 307
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 304
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 303
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 299
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 299
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 295
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 292
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 290
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 284
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 282
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells 280
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 279
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 276
Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 272
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 268
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 267
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 267
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 263
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 259
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 253
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 251
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the fondazione Italiana linfomi 244
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 244
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 240
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 239
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 229
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? 222
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL) 222
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 218
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 214
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 211
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial 208
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 208
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 178
Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi 174
Khorana score and histotype predicts incidence of early venous thromboembolism in Non-Hodgkin lymphomas: A Pooled-Data analysis of 12 clinical trials of fondazione italiana linfomi (FIL) 172
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi 169
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 169
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 163
Diagnosi di crioproteinemia: preziosa collaborazione tra laboratorio e clinica per la corretta gestione di una patologia rara 163
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 162
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 120
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 120
Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments (Annals of Hematology, (2020), 99, 2, (277-282), 10.1007/s00277-019-03893-7) 114
The impact of healthy lifestyles on late sequelae in classical hodgkin lymphoma and diffuse large b-cell lymphoma survivors. A systematic review by the fondazione italiana linfomi 111
Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. A Systematic Review by the Fondazione Italiana Linfomi 109
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 109
Management of multiple myeloma|Terapia del mieloma multiplo 84
Totale 20.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.307
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.307
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021588 0 0 0 0 0 0 0 0 0 251 224 113
2021/20221.487 62 110 181 64 28 119 83 112 150 112 266 200
2022/20231.396 152 185 113 141 152 196 25 131 180 13 66 42
2023/20241.099 58 38 75 106 232 72 199 101 33 19 63 103
2024/20253.171 104 40 76 245 645 494 220 181 361 119 255 431
2025/20265.716 406 254 440 794 1.106 417 724 390 648 537 0 0
Totale 20.137